Abstract
The experts of the Department for Medicine Safety Evaluation of the Scientific Centre for Expert Evaluation of Medicinal Products analysed administrative decisions of international pharmacovigilance regulatory authorities on the necessary labelling updates. The analysis revealed 16 decisions containing safety updates for the following medicines registered in Russia: avatrombopag, amphotericin B, acetazolamide, belimumab, bendamustine, hydrocortisone, dabrafenib, dexamethasone, denosumab, ibuprofen, cortisone, prednisolone, trametinib, nilotinib, pirfenidone, and cefotaxime.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have